Moderna (MRNA) climbed to $81.42, up 169% annually. Analysts set average target at $37 while insiders sold $6.1M worth of ...

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in ...

In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.

Moderna just received fantastic news.

VWAP resistance, R&D wins, Q1 revenue surge, and mRNA-1010 risks missed flu contracts—the rating shifts to Sell. Click for an ...